Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes.

Al-Bazz, Dalal Y and Wilding, John Ph ORCID: 0000-0003-2839-8404 (2020) Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes. Future Cardiol, 16 (2). pp. 77-88. ISSN 1479-6678, 1744-8298

Text Dapagliflozin Review Main Document Clean (no tracking) Updated DA JW.docx - Author Accepted Manuscript Download (250kB)

Abstract

The relationship between cardiovascular disease, heart failure (HF) and Type-2 diabetes (T2DM) is widely recognized. Cardiovascular (CV) outcome trials are required for all new glucose-lowering agents to confirm safety with respect to CV risk. CV outcome trials with sodium glucose cotransporter 2 inhibitors have shown CV benefit, with reductions in major CV events and HF. This review focuses on the DECLARE-TIMI 58 trial with dapagliflozin in T2DM, which showed noninferiority for major adverse cardiovascular events and reduction in hospitalization for HF and associated CV mortality in a broad range of patients with T2DM. The DAPA-HF trial of dapagliflozin in people with HF with reduced ejection fraction with and without T2DM confirms benefits for those with HF.

Item Type:	Article
Uncontrolled Keywords:	CVD, DECLARE, SGLT2i, T2DM, dapagliflozin
Depositing User:	Symplectic Admin
Date Deposited:	16 Jan 2020 15:41
Last Modified:	07 Dec 2024 21:01
DOI:	10.2217/fca-2019-0065
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3070870